Skip to main content
Premium Trial:

Request an Annual Quote

Paul Billings

Natera has appointed Paul Billings as its chief medical officer and senior vice president of medical affairs, where he will help lead efforts across the firm's reproductive health, oncology, and new emerging businesses. Billings is a board-certified internist and clinical geneticist with more than 30 years of experience in genomics and molecular medicine, having held academic and research appointments at Harvard University, UC San Francisco, Stanford University, and UC Berkeley.

Prior to joining Natera, Billings was chief medical officer of Life Technologies, consulting CMO of the genetic sciences division of Thermo Fisher Scientific, and senior physician at Laboratory Corporation of America. He has served on the scientific advisory board of the US Food and Drug Administration, the genomic medicine advisory committee at the Department of Veterans Affairs, and the HHS Secretary’s Advisory Committee on Genomics, Health and Society. His work formed the basis of the Genetic Information Nondiscrimination Act of 2008 (GINA).

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.